|
KMID : 1128320180160020023
|
|
Electrolytes & Blood Pressure
2018 Volume.16 No. 2 p.23 ~ p.26
|
|
|
Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
|
|
Kim Ha-Yeon
Lee Seung-Jin
Kim Byung-Ki
Kim Min-Ah
Bae Eun-Hui
Ma Seong-Kwon
Kim Soo-Wan
|
|
|
Abstract
|
|
|
|
A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.
|
|
|
KEYWORD
|
|
|
Autosomal dominant polycystic kidney disease, Tolvaptan, V2-antagonist, Long-term outcome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|